Metallothionein Reverses the Harmful Effects of Angiotensin II on the Diabetic Heart**Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.

Journal of the American College of Cardiology

Volumn 52, Issue 8, 2008, Pages 667-669

  De Mello, Walmor C ^a  

^a UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

Author keywords

cardiac; diabetes; oxidative stress; remodeling

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METALLOTHIONEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; OLMESARTAN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; THIOREDOXIN; VALSARTAN; VON WILLEBRAND FACTOR;

ATHEROSCLEROSIS; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CELL DEATH; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFECT; EDITORIAL; ENZYME ACTIVATION; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART FAILURE; HUMAN; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; VITAMIN SUPPLEMENTATION; ZINC DEFICIENCY;

ANGIOTENSIN II; CARDIOMYOPATHIES; DIABETIC ANGIOPATHIES; HUMANS; METALLOTHIONEIN; NADP; OXIDATIVE STRESS;

EID: 48949103230     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.04.053     Document Type: Editorial

References (34)

1. Cooper M.E. The role of the renin angiotensin aldosterone system in diabetes and its vascular complications. Am J Hypertens 17 (2004) 16S-20S
2. Chen S., Evans T., Mukherjee K., Karmazyn M., and Chakrabarti S. Diabetes-induced myocardial structural changes: role of endothelin-1 and its receptors. J Mol Cell Cardiol 32 (2000) 1621-1629
3. Machackova J., Liu X., Lukas A., and Dhalla N.S. Renin-angiotensin blockade attenuates cardiac myofibrillar remodeling in chronic diabetes. Mol Cell Biochem 261 (2004) 271-278
4. De Mello W.C. Impaired cell communication in the diabetic heart. The role of the renin angiotensin system. Mol Cell Biochem 296 (2007) 53-58
5. Picano E. Diabetic cardiomyopathy. The importance of being earliest. J Am Coll Cardiol 42 (2003) 454-457
6. Adeghate E. Molecular and cellular basis of the aetiology and management of diabetic cardiomyopathy: a short review. Mol Cell Biochem 261 (2004) 187-191
7. McMurray J.J., and Stewart S. Epidemiology, etiology and prognosis of heart failure. Heart 83 (2000) 596-602
8. Zhou G., Li X., Hein D.W., et al. Metallothionein suppresses angiotensin II-induced nicotinamide adenine dinucleotide phosphate oxidase activation, nitrosative stress, apoptosis, and pathological remodeling in the diabetic heart. J Am Coll Cardiol 52 (2008) 655-666
9. Cai L., Klein J.B., and Kang X.J. Metallothionein inhibits peroxynitrite-induced DNA and lipoprotein damage. J Biol Chem 275 (2000) 38957-38960
10. Isman M.S., and Loots du T. Diabetes, metallothionein and zinc interaction: a review. Biofactors 29 (2007) 203-212
11. Cohen N., and Golik A. Zinc balance and medications commonly used in the management of heart failure. Heart Fail Rev 11 (2006) 19-24
12. Griendling K.K., Sorescu D., and Ushio-Fukai M. NAD(P)H oxidase. Role in cardiovascular biology and disease. Circ Res 86 (2000) 494-501
13. Lauersen J.B., Rajagopalan S., Galis Z., Tarpey M., Freeman B.A., and Harrison D.G. Role of superoxide in angiotensin II-induced but not catechol-induced hypertension. Circulation 95 (1997) 588-593
14. Diet F., Pratt R.E., Berry G.J., Momose N., Gibbons G.H., and Dzau V.J. Increased accumulation of tissue ACE in human atherosclerotic coronary disease. Circulation 94 (1996) 2756-2767
15. Hornig B., Landmesser U., Kohler C., et al. Comparative effects of ACE inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation 103 (2001) 799-805
16. Cruzado M.C., Risler N.R., Miatello R.M., Yao G., Schiffrin E.L., and Touyz R.M. Vascular smooth muscle cell NAD(P)H oxidase activity during the development of hypertension: effect of Ang II and role of insulin like growth factor-1 receptor transactivation. Am J Hypertens 18 (2005) 81-87
17. Griendling K.K., Minieri C.A., Ollerenshaw J.D., and Alexander R.W. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74 (1994) 1141-1148
18. Kamik A.A., Fields A.V., and Shannon R.P. Diabetic cardiomyopathy. Curr Hypertens Rep 9 (2007) 467-473
19. Yamashita C., Hayahi T., Mori T., et al. Angiotensin II receptor blocker reduces oxidative stress and attenuates hypoxia-induced left ventricular remodeling in apolipoprotein E-knockout mice. Hypertens Res 30 (2007) 1219-1230
20. Miyajima K., Minatogushi S., Ito Y., et al. Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension. Hypertens Res 30 (2007) 307-313
21. Outdit G.Y., Kassiri Z., Patel M.P., et al. Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardiovasc Res 75 (2007) 29-39
22. Digiesi D., Lenuzza M., and Digiese G. Prospects for the use of antioxidant therapy in hypertension. Ann Ital Med Int 16 (2001) 93-100
23. Duffy S.J., Gokce N., Holbrook M., et al. Treatment of hypertension with ascorbic acid. Lancet 354 (1999) 2048-2049
24. Stephens N.G., Parsons A., Schofield P.M., Kelly F., Cheeseman K., and Mitchinson M.J. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 347 (1996) 781-786
25. Salonen R.M., Nyyssonen K., and Kaikkomen J. Six year effect of vitamin C and E supplementation on atherosclerotic progression: the Antioxidant Supplementation in Atherosclerosis Prevention. (ASAP)Study. Circulation 107 (2003) 947-953
26. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell"ínfarto miocardico. Lancet 354 (1999) 447-455
27. Hilenski L.L., Clempus R.E., Quinn M.T., et al. Distinct subcellular localizations of Nox1 and No4 in vascular smooth muscle cells. Atheroscler Tromb Vac Biol 24 (2004) 677-683
28. Harrisdon D.G., and Dilakov S. Oxidative events in cell and vascular biology. In: Re R., DiPette D.J., Schiffrin E.L., and Sowers J.R. (Eds). Molecular Mechanisms in Hypertension (2006), Taylor and Francis, New York, NY 297-320
29. Webster K.A. Stress hyperglycemia and enhanced sensitivity to myocardial infarction. Curr Hypertens Rep 10 (2008) 78-84
30. Neuman R.B., Bloom H.L., Shukrullah I., et al. Oxidative stress markers are associated with persistent atrial fibrillation. Clin Chem 53 (2007) 1652-1657
31. Hoshino Y., Shioji K., Nakamura H., and Yodoi J. From oxygen sensing to heart failure: role of thioredoxin. Antioxid Redox Signal 9 (2007) 689-699
32. Ray K.K., Cannon C.P., Morrow D.A., et al. Synergistic relationship between hyperglycemia and inflammation with respect to clinical outcomes in non-ST-elevation coronary syndromes: analysis from OPUS-TIMI 16 and TACTICS-TIMI 18. Eur Heart J 28 (2007) 806-813
33. Hamblin M., Smith H.M., and Hill M.F. Dietary supplementation with vitamin E ameliorates cardiac failure in type 1 diabetic cardiomyopathy by suppressing myocardial generation of 8-iso prostaglandin F2alpha and oxidized glutathione. Card Fail 13 (2007) 884-892
34. Guha A., Harmancey R., and Taegtmeyer H. Nonischemic heart failure in diabetes mellitus. Curr Opin Cardiol 23 (2008) 241-248